Back to Search
Start Over
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.
- Source :
-
Oncoimmunology [Oncoimmunology] 2022 Mar 21; Vol. 11 (1), pp. 2054758. Date of Electronic Publication: 2022 Mar 21 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- We previously found that activated CD8 <superscript>+</superscript> T-cells increase expression of PD-1, which can be attenuated in the presence of specific Toll-like receptor (TLR) agonists, mediated by IL-12 secreted by professional antigen-presenting cells. While these CD8 <superscript>+</superscript> T-cells had greater anti-tumor activity, T-cells stimulated by different TLR had different gene expression profiles. Consequently, we sought to determine whether combinations of TLR agonists might further affect the expression of T-cell checkpoint receptors and improve T-cell anti-tumor immunity. Activation of CD8 <superscript>+</superscript> T-cells in the presence of specific TLR ligands resulted in decreased expression of PD-1, LAG-3, and CD160, notably with combinations of TLR1/2, TLR3, and TLR9 agonists. Immunization of E.G7-OVA or TRAMP-C1 tumor-bearing mice with peptide or DNA vaccines, co-administered with combination of TLR3 and TLR9 agonists, showed greater suppression of tumor growth. The anti-tumor effect of TLR1/2 and/or TLR9, but not TLR3, was abrogated in IL-12KO mice. RNA sequencing of TLR-conditioned CD8 <superscript>+</superscript> T-cells revealed IL-12 pathway activation, and type 1 IFN pathway activation following TLR3 stimulation. Our results provide a mechanistic rationale for the choice of optimal combinations of TLR ligands to use as adjuvants to improve the efficacy of anti-tumor vaccines.<br />Competing Interests: DGM has ownership interest, has received research support, and serves as consultant to Madison Vaccines, Inc., which has licensed material described in this manuscript. The other author has no relevant potential conflicts of interest.<br /> (© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Subjects :
- Adjuvants, Immunologic
Animals
Immune Checkpoint Proteins
Interferons
Ligands
Mice
Programmed Cell Death 1 Receptor
Toll-Like Receptor 1
Toll-Like Receptor 3 agonists
Toll-Like Receptor 3 genetics
Toll-Like Receptor 9 agonists
Toll-Like Receptor 9 genetics
CD8-Positive T-Lymphocytes
Interleukin-12
Toll-Like Receptors agonists
Toll-Like Receptors genetics
Subjects
Details
- Language :
- English
- ISSN :
- 2162-402X
- Volume :
- 11
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Oncoimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 35340661
- Full Text :
- https://doi.org/10.1080/2162402X.2022.2054758